ARLINGTON, Tenn.–(BUSINESS WIRE)–MicroPort Orthopedics, a medical device company that develops and manufactures cutting-edge joint replacement implants and approaches, today announced the launch of its Procotyl® Prime Acetabular Cup System.

“At MicroPort Orthopedics, we embrace the constant advance in orthopedic medicine, and have a deep commitment to creating products that make patients’ lives better,” said Aurelio Sahagun, President. “The Procotyl^® Prime Acetabular Cup System, with its best-in-class features, is a great example of this commitment, as it not only strengthens our position as a leader in surgical joint replacement, but also complements our existing products and surgical approaches to help patients return to full function faster.”

The Procotyl® Prime Acetabular Cup System, which is the next step in the evolution of the successful Dynasty® Acetabular Cup System, received 510k Clearance from the U.S. Food & Drug Administration in late June.

“Procotyl® Prime’s design is a culmination of over 20 years of market experience coupled with intelligent design and engineering,” said Dr. James Chow, Director of Orthopedics Hip & Joint at Phoenix St. Luke’s Medical Center. “We set out to design an implant optimized for highly-crosslinked polyethylene and modern 3D fixation surfaces, allowing us to eliminate compromises. The result is a shell that is strong and flexible, has maximized poly thickness and robust pull-out strength, all while allowing the versatility of large head options in the smallest sizes.”

In addition to the benefits of the implant, the Procotyl® Prime system is the first on the market designed with simple, versatile instrumentation to support a variety of surgical approaches, including all of MicroPort’s soft-tissue sparing philosophies.

Dr. Brad Penenberg, Chief of Arthroplasty Service at Cedars-Sinai Hospital, said, “Procotyl® Prime is the first acetabular component adapted for MicroPort’s novel portal-assisted acetabular instrumentation. This unique approach facilitates preservation of soft tissue, fast patient recovery, and direct acetabular visualization.”

For more information about the Procotyl® Prime Acetabular Cup System or MicroPort Orthopedics, visit www.ortho.microport.com or follow the brand on Twitter and Facebook.

About MicroPort Orthopedics
Established in January 2014, MicroPort Orthopedics Inc. is the fifth largest multinational producer of hip and knee implants and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative OrthoRecon products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japanese, Latin American and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/.

About MicroPort Scientific
MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com.

Forward-Looking Statements
Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.

Copyright © 2017 MicroPort Scientific Corporation

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech (Nasdaq:EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today that the new Truliant® Knee System’s surgical instrumentation received a bronze award in the 2017 International Design Excellence Awards (IDEA®). Sponsored annually by the Industrial Designers Society of America (IDSA), the 2017 winners were recognized on Aug. 19 in Atlanta, Ga.

Exactech’s Truliant Knee System offers a comprehensive portfolio of implants and instrumentation to help surgeons address the remaining clinical challenges of total knee replacement. The goal of the ergonomic instrumentation design is to help surgeons make accurate and consistent bone cuts and adjustments to the joint during total knee arthroplasty. The designs embody Exactech’s brand strategy and offer surgeons a reproducible and efficient experience through:

• Texturing and blue accents which indicate touch points for adjustability and functionality,
• Elegant black background for high-contrast markings and easily identified grip locations,
• Dials that offer tactile and auditory feedback with every click, and
• Textured surfaces on handles and specific points which provide a secure grip and accommodate mechanical and functional needs of the user.

The industrial design project, a first for the company, was led by Exactech’s knee business segment. According to Laurent Angibaud, director of knee and CAS engineering at Exactech, “Merging customer input with solid design principles, our industrial design and technical engineers optimized the function and appearance of new instrumentation to improve user experience, which is core to our surgeon-focused culture. This award demonstrates Exactech’s commitment to developing solutions to address real clinical needs.”

Design Team Surgeon Sudheer Karlakki, FRCS (Orth) at the Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust in the United Kingdom commented: “Truliant provides a harmonious balance of both functional improvements and format enhancements with a color scheme that aligns with the Exactech brand. An important design emphasis was placed on users being able to pick up any instrument and easily get a sense of its important working features. With its ergonomic and intuitive design intentions, surgeons and hospital staff should have an instant connection to the system; that is the real beauty of Truliant.”

Surgical teams across the country have been experiencing the benefits of Truliant through the system’s initial rollout and first cases. According to Tomas Nemickas, MD of Illinois Bone and Joint Institute, “My impression of the new Truliant system is that Exactech has done a fantastic job at fine-tuning a new set of instruments to allow for a more predictable and reproducible outcome. The award is well deserved and demonstrates what I have experienced firsthand with the Truliant Knee System.”

Certified Surgical Technologist Mary Joy Tanada from Stanford University said, “I was unbelievably surprised with the ease of use and simplicity of the Truliant instrumentation. The tools are well balanced in surgeons’ hands and easy to understand. The system is modular and organized into four trays that are all interchangeable based on needs of the case, making it streamlined and efficient for the entire surgical team.”

IDEA is a premier international design competition sponsored annually by the IDSA and judged by renowned design experts from around the world. The 2017 competition attracted hundreds of entries from 54 countries on six continents.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

A current investment profile on Exactech (Nasdaq: EXAC) is available online at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.